


2021 Financial Highlights


Revenue by Species[†]



■ Dogs and Cats¹ 58%
 ■ Horses¹ 3%
 ■ Fish² 2%
 ■ Sheep and Other² 1%


¹ Companion Animal 61%
² Livestock 39%

Revenue by Product Category[†]



■ Vaccines 22%
 ■ Medicated Feed Additives 5%
 ■ Animal Health 5%
 ■ Diagnostics 5%
 ■ Other Non-Pharmaceuticals 3%

Revenue by Top Markets[†]




■ United States 53%
 ■ Chile 2%
 ■ China 5%
 ■ Mexico 2%
 ■ Brazil 4%
 ■ France 2%
 ■ Australia 3%
 ■ Spain 2%
 ■ United Kingdom 3%
 ■ Italy 1%
 ■ Canada 3%
 ■ Other Emerging Markets 10%
 ■ Japan 2%
 ■ Other Developed Markets 6%
 ■ Germany 2%

Revenue by Product Concentration



■ All Other 53%
 ■ Top Ten Product Lines 47%
 (Top Five make up 33%)

Revenue Growth and Adjusted EBIT Margin



○ Adjusted EBIT Margin*

* Adjusted EBIT margin (a non-GAAP financial measure) is defined as adjusted net income attributable to Zoetis excluding (i) interest expense and interest income and (ii) income taxes (all as included in adjusted net income), expressed as a percentage of revenue.

** Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income attributable to Zoetis and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items.

† Represents operational revenue growth (a non-GAAP financial measure), which is defined as revenue growth excluding the impact of foreign exchange. Reported revenue growth, including the impact of foreign exchange, was 7% for 2019, 7% for 2020 and 16% for 2021.

‡ Revenue charts by species, product category and top market exclude revenues associated with Client Supply Services and Human Health, which represented 1% of total 2021 revenue.

\$Millions (except per share data)

	2019	2020	2021
Revenue	\$ 6,260	\$ 6,675	\$ 7,776
Net Income Attributable to Zoetis	\$ 1,500	\$ 1,638	\$ 2,037
Adjusted Net Income Attributable to Zoetis**	\$ 1,755	\$ 1,844	\$ 2,240
Diluted Earnings Per Share	\$ 3.11	\$ 3.42	\$ 4.27
Adjusted Diluted Earnings Per Share**	\$ 3.64	\$ 3.85	\$ 4.70
Net Cash Provided by Operating Activities	\$ 1,795	\$ 2,126	\$ 2,213
Research & Development Expense	\$ 457	\$ 463	\$ 508